Please enter keyword
OK
Please enter keyword
OK
Technical Q & A
GPCR technology platform GPCR technology platform GPCR technology platform GPCR technology platform GPCR technology platform
Taking human antibody renmice (renmab, renlite, rennano) as the cornerstone, the whole process technology platform from antibody discovery, antibody engineering, in vitro analysis to CMC process development has been constructed, and an international first-class antibody development talent team has been created. Relying on the world's leading single-cell antibody discovery technology, we can quickly and high-throughput complete antibody discovery. At the same time, thanks to comprehensive technical means including phage display technology and hybridoma technology, we can ensure that we have enough confidence to complete the challenge in the face of difficult targets. With our profound accumulation in the field of gene editing technology, through target knockout, the whole human antibody developed by us has richer epitope diversity and multi species crossover, which allows the target verification to be completed in an economic way and quickly through in vivo experiments, and screening antibody drug candidates with potential pharmaceutical value. Once candidate molecules are obtained, the optimization of antibody drugs can be quickly completed and high expression antibody production cell lines can be obtained through strong antibody analysis and antibody engineering technology. Through advanced engineering methods, the development of antibody candidate molecules for 1400 targets is planned to be completed within three years, so as to quickly transform science into drugs and benefit the majority of patients.
Dual reactance technology platform
Taking human antibody renmice (renmab, renlite, rennano) as the cornerstone, the whole process technology platform from antibody discovery, antibody engineering, in vitro analysis to CMC process development has been constructed, and an international first-class antibody development talent team has been created. Relying on the world's leading single-cell antibody discovery technology, we can quickly and high-throughput complete antibody discovery. At the same time, thanks to comprehensive technical means including phage display technology and hybridoma technology, we can ensure that we have enough confidence to complete the challenge in the face of difficult targets. With our profound accumulation in the field of gene editing technology, through target knockout, the whole human antibody developed by us has richer epitope diversity and multi species crossover, which allows the target verification to be completed in an economic way and quickly through in vivo experiments, and screening antibody drug candidates with potential pharmaceutical value. Once candidate molecules are obtained, the optimization of antibody drugs can be quickly completed and high expression antibody production cell lines can be obtained through strong antibody analysis and antibody engineering technology. Through advanced engineering methods, the development of antibody candidate molecules for 1400 targets is planned to be completed within three years, so as to quickly transform science into drugs and benefit the majority of patients.
SUPCE
Taking human antibody renmice (renmab, renlite, rennano) as the cornerstone, the whole process technology platform from antibody discovery, antibody engineering, in vitro analysis to CMC process development has been constructed, and an international first-class antibody development talent team has been created. Relying on the world's leading single-cell antibody discovery technology, we can quickly and high-throughput complete antibody discovery. At the same time, thanks to comprehensive technical means including phage display technology and hybridoma technology, we can ensure that we have enough confidence to complete the challenge in the face of difficult targets. With our profound accumulation in the field of gene editing technology, through target knockout, the whole human antibody developed by us has richer epitope diversity and multi species crossover, which allows the target verification to be completed in an economic way and quickly through in vivo experiments, and screening antibody drug candidates with potential pharmaceutical value. Once candidate molecules are obtained, the optimization of antibody drugs can be quickly completed and high expression antibody production cell lines can be obtained through strong antibody analysis and antibody engineering technology. Through advanced engineering methods, the development of antibody candidate molecules for 1400 targets is planned to be completed within three years, so as to quickly transform science into drugs and benefit the majority of patients.
EGE
Taking human antibody renmice (renmab, renlite, rennano) as the cornerstone, the whole process technology platform from antibody discovery, antibody engineering, in vitro analysis to CMC process development has been constructed, and an international first-class antibody development talent team has been created. Relying on the world's leading single-cell antibody discovery technology, we can quickly and high-throughput complete antibody discovery. At the same time, thanks to comprehensive technical means including phage display technology and hybridoma technology, we can ensure that we have enough confidence to complete the challenge in the face of difficult targets. With our profound accumulation in the field of gene editing technology, through target knockout, the whole human antibody developed by us has richer epitope diversity and multi species crossover, which allows the target verification to be completed in an economic way and quickly through in vivo experiments, and screening antibody drug candidates with potential pharmaceutical value. Once candidate molecules are obtained, the optimization of antibody drugs can be quickly completed and high expression antibody production cell lines can be obtained through strong antibody analysis and antibody engineering technology. Through advanced engineering methods, the development of antibody candidate molecules for 1400 targets is planned to be completed within three years, so as to quickly transform science into drugs and benefit the majority of patients.